ČESKÁ UROLOGIE / CZECH UROLOGY – 3 / 2020

213 ORIGINÁLNÍ PRÁCE Ces Urol 2020; 24(3): 207–213 5. Poršová M, Kolombo I, Porš J, Pabišta R. Možnosti prevence recidivujících infekcí močových cest. Urolog. praxi 2006; 5: 204–209. 6. Ciani O, Arendsen E, Romancik M, et al. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case – control study. BMJ Open 2016; 6: e009669. doi: 10.1136/bmjopen-2015-009669. 7. Parsons CL, Greenspans C, Mulholland S. The primary antibacterial defense mechanism of the bladder. Invest Urol 1975; 13: 72–76. 8. Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 1996; 156(1): 45–48. 9. Rooney P, Srivastava A, Watson L, Quinlan LR, Pandit A. Hyaluronic acid decreases IL-6 and IL-8 se‑ cretion and permeability in an inflammatory model of interstitial cystitis. Acta Biomater 2015; 19: 66–75. doi: 10.1016/j.actbio.2015. 02. 030. 10. Tay H, Parsons CL, Stein PC. Electrophysiologic monitoring of the effects of soluble virulence factors pro‑ duced by Escherichia coli infection in urine. Urology 1996; 48(3): 389–392. doi: 10.1016/s0090-4295(96)00209-9. 11. Cicione A, Cantiello F, Ucciero G, et al. Intravesical treatment with highly‑concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: results from a multicentre survey. Can Urol Assoc J 2014; 8(9–10): E721–E727. doi: 10.5489/cuaj.1989. 12. Goddard JC, Janssen DAW. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta‑analysis. Int Urogynecol J 2018; 29(7): 933–942. doi: 10.1007/ s00192-017-3508-z. 13. Simmering JE, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998–2011. Open Forum Infect, DiS. 2017; 4(1): ofw281. Published 2017 Feb 24. doi: 10.1093/ofid/ofw281. 14. Albert X, Huertas I, Pereiró II, et al. Antibiotics for preventing recurrent urinary tract infection in non­ ‑pregnant women. Cochrane Database Syst Rev 2004; 2004(3): CD001209. doi: 10.1002/14651858.CD001209. pub2. 15. Rejchrt M, Havlová K, Kříž J. Prevence recidivujících uroinfekcí intravezikální instilací kyseliny hyaluro‑ nové a chondroitinsulfátu u pacientů po míšním poranění. Urol. praxi 2015; 16: 43. 16. Erikse BA. Randomized, open, parallel‑group study on the preventive effect of an estradiol‑releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999; 180(5): 1072–1079. doi: 10.1016/s0002-9378(99)70597-1. 17. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329(11): 753–756. doi: 10.1056/NEJM199309093291102. 18. Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical ad‑ ministration of hyaluronic acid and chondroitin sulphate: a placebo‑controlled randomised trial [published correction appears in Eur Urol. 2011 Jul; 60(1): 193]. Eur Urol 2011; 59(4): 645–651. doi: 10.1016/j.eururo.2010.12.039. 19. Arya LA, Northington GM, Asfaw T, Harvie H, Malykhina A. Evidence of bladder oversensitivity in the absence of an infection in premenopausal women with a history of recurrent urinary tract infections. BJU Int. 2012; 110(2): 247–251. doi: 10.1111/j.1464-410X.2011.10766.x. 20. Gülpınar O, Kayış A, Süer E, et al. Clinical comparision of intravesical hyaluronic acid and hyaluronic acid‑chondroitin sulphate therapy for patients with bladder pain syndrome/interstitital cystitis. Can Urol Assoc J 2014; 8(9–10): E610–E614. doi: 10.5489/cuaj.2036. 21. De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J 2012; 23(12): 1707–1713. doi: 10.1007/s00192-012-1794-z.